Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colon cancer.

Roberto Labianca1, Giordano Beretta, Gemma Gatta

  • 1Ospedali Riuniti, Bergamo, Italy.

Critical Reviews in Oncology/Hematology
|July 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

Journal for immunotherapy of cancer·2026
Same author

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50.

Cancer cell international·2026
Same author

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.

NPJ precision oncology·2026
Same author

FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same journal

Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

Critical reviews in oncology/hematology·2026
Same journal

Remodeling the Immune Microenvironment: Engineering IL-2 Variants to Overcome Clinical Bottlenecks in PD-1 Inhibitor plus Chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted Management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
Same journal

Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

Critical reviews in oncology/hematology·2026
See all related articles

Colon cancer treatment advances include effective adjuvant chemotherapy and optimized surgery. New targeted drugs like cetuximab and bevacizumab show promise, improving patient outcomes.

Area of Science:

  • Oncology
  • Gastrointestinal Cancer Research

Background:

  • Colon cancer is a leading global cause of cancer mortality.
  • Significant progress has been made in colon cancer treatment strategies.

Purpose of the Study:

  • To summarize recent advances in colon cancer treatment.
  • To provide updated recommendations for clinical practice.

Main Methods:

  • Review of recent clinical research and treatment outcomes.
  • Evaluation of adjuvant chemotherapy, surgical optimization, and targeted therapies.

Main Results:

  • Adjuvant chemotherapy is effective, particularly for stage III patients.
  • Optimized surgical techniques reduce morbidity and improve results.

Related Experiment Videos

  • Targeted drugs (cetuximab, bevacizumab) show efficacy, especially with chemotherapy.

    • Conclusions:

    • Updated management recommendations are crucial for optimal patient outcomes.
    • Integrating new findings into practice enhances clinical research and patient care.